

Original French opinion adopted by the Transparency Committee.

The legally binding text is the original French opinion version.

SUMMARY

Vaccines against invasive meningococcal disease, serogroups A, C, W, Y and B

BEXSERO, MENQUADFI, MENVEO, NIMENRIX and TRUMENBA

Modification of listing conditions following the 2025 update to the HAS recommendations

Adopted by the Transparency Committee on 10 September 2025

Summary of opinion

Favourable opinion for extension of reimbursement in the active immunisation of individuals against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W-135, Y and B, in accordance with the current HAS recommendations of 13/03/2025¹ and 17/07/2025².

Transparency Committee's conclusions

Considering all of this information, the Committee takes note of the new recommendations updating the vaccination strategy against IMD, which are not of a nature to modify its previous conclusions.

This document and its bibliographic reference are available to download at www.has-sante.fr 

This opinion is published subject to intellectual property rights

Haute Autorité de Santé – Communication and Information Department

5 avenue du Stade de France – 93218 SAINT-DENIS LA PLAINE CEDEX – France. Tel.: +33 (0)1 55 93 70 00

© Haute Autorité de santé – September 2025

¹ Haute Autorité de Santé - Recrudescence des infections invasives à méningocoques : de nouvelles recommandations sur le rattrapage vaccinal [Rise in invasive meningococcal disease: new recommendations for vaccination catch-up]

² Haute Autorité de Santé - Opinion No. 2025.0040/AC/SESPEV dated 17 July 2025 of the HAS Board relative to the addition of vaccines against invasive meningococcal disease caused by serogroups A, C, W, Y and B to the order setting the list of vaccines mentioned in article L. 5122-6 of the French Public Health Code

Clinical benefit

- Invasive meningococcal disease (IMD) is a serious transmissible infection, primarily manifested in the form of meningitis or meningococemia, the most severe form being *purpura fulminans*.
- The vaccines concerned are preventive.
- The efficacy (immunogenicity)/adverse effects ratio is high.
- Given their different marketing authorisation scopes, NIMENRIX, MENQUADFI and MENVEO are available against serogroups ACWY from the age of 6 weeks, 12 months and 2 years, respectively. Concerning serogroups B, BEXSERO is available from the age of 2 months, and TRUMENBA from the age of 10 years.

→ Public health benefit

These vaccines are likely to have an additional impact on public health.

The update to the vaccine strategy in accordance with the current HAS recommendations of 13/03/2025 and 17/07/2025 is not of a nature to modify the clinical benefit, which remains substantial in the active immunisation of individuals against invasive meningococcal disease caused by *Neisseria meningitidis* groups A, C, W, Y and B.

The Committee issues a favourable opinion for inclusion in both the list of covered drugs for outpatients and the list of covered drugs for inpatients approved for use in the active immunisation of individuals against invasive meningococcal disease caused by *Neisseria meningitidis* groups A, C, W, Y and B in accordance with the current HAS recommendations of 13/03/2025 and 17/07/2025.

- **Recommended reimbursement rate for inclusion in the list of covered drugs for outpatients: 65%**

Clinical Added Value

The update to the vaccine strategy in accordance with the current HAS recommendations of 13/03/2025 and 17/07/2025 is not of a nature to modify the Transparency Committee's previous conclusions.